Nicotinic Partial Agonists Varenicline and Sazetidine-A Have Differential Effects on Affective Behavior

Overview

Journal J Pharmacol Exp Ther

Specialty Pharmacology

Date 2010 May 4

PMID 20435920

Citations 48

Authors

Jill R Turner

Laura M Castellano

Julie A Blendy

Affiliations

Soon will be listed here.

Abstract

Clinical and preclinical studies suggest that nicotinic acetylcholine receptors are involved in affective disorders; therefore, the potential therapeutic value of nicotinic partial agonists as treatments of these disorders is of growing interest. This study evaluated the effects of acute and chronic administration of nicotine and the alpha4beta2 nicotinic partial agonists varenicline and sazetidine-A in mouse models of anxiety and depression. Acutely, only nicotine and varenicline had anxiolytic effects in the marble-burying test and in the novelty-induced hypophagia (NIH) test. In contrast, in animal models of antidepressant efficacy, such as the forced swim and the tail suspension test, only acute sazetidine-A had significant antidepressant-like effects. The NIH test provides an anxiety-related measure that is sensitive to the effects of chronic but not acute antidepressant treatment. Chronic nicotine and chronic sazetidine-A treatment were effective in this paradigm, but varenicline was ineffective. These results suggest that the partial agonists varenicline and sazetidine-A may have diverse therapeutic benefits in affective disorders.

Citing Articles

Sex differences in contextual fear conditioning and extinction after acute and chronic nicotine treatment.

Keady J, Hessing M, Songrady J, McLaurin K, Turner J Biol Sex Differ. 2024; 15(1):88.

PMID: 39482781 PMC: 11529327. DOI: 10.1186/s13293-024-00656-6.

Dynamic effects of ventral hippocampal NRG3/ERBB4 signaling on nicotine withdrawal-induced responses.

Fisher M, Prantzalos E, ODonovan B, Anderson T, Sahoo P, Twiss J Neuropharmacology. 2024; 247:109846.

PMID: 38211698 PMC: 10923109. DOI: 10.1016/j.neuropharm.2024.109846.

Age-specific impacts of nicotine and withdrawal on hippocampal neuregulin signalling.

Keady J, Fisher M, Anderson E, LeMalefant R, Turner J Eur J Neurosci. 2022; 56(6):4705-4719.

PMID: 35899607 PMC: 9710301. DOI: 10.1111/ejn.15780.

Enhancement of alcohol aversion by the nicotinic acetylcholine receptor drug sazetidine-A.

Touchette J, Moen J, Robinson J, Lee A Addict Biol. 2020; 26(2):e12908.

PMID: 32329567 PMC: 7584768. DOI: 10.1111/adb.12908.

Oral sazetidine-A, a selective α4β2* nicotinic receptor desensitizing agent, reduces nicotine self-administration in rats.

Rezvani A, Wells C, Slade S, Xiao Y, Kellar K, Levin E Pharmacol Biochem Behav. 2019; 179:109-112.

PMID: 30794849 PMC: 6570822. DOI: 10.1016/j.pbb.2019.02.007.

References

Picciotto M, Addy N, Mineur Y, Brunzell D . It is not "either/or": activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood. Prog Neurobiol. 2008; 84(4):329-42. PMC: 2390914. DOI: 10.1016/j.pneurobio.2007.12.005. View

Picciotto M, Brunzell D, Caldarone B . Effect of nicotine and nicotinic receptors on anxiety and depression. Neuroreport. 2002; 13(9):1097-106. DOI: 10.1097/00001756-200207020-00006. View

Markou A, Kosten T, Koob G . Neurobiological similarities in depression and drug dependence: a self-medication hypothesis. Neuropsychopharmacology. 1998; 18(3):135-74. DOI: 10.1016/S0893-133X(97)00113-9. View

Lumpkin M, Kellar K . Acute effects of nicotine on prolactin release in the rat: agonist and antagonist effects of a single injection of nicotine. J Pharmacol Exp Ther. 1990; 252(1):15-20. View

Stoker A, Semenova S, Markou A . Affective and somatic aspects of spontaneous and precipitated nicotine withdrawal in C57BL/6J and BALB/cByJ mice. Neuropharmacology. 2008; 54(8):1223-32. PMC: 2496875. DOI: 10.1016/j.neuropharm.2008.03.013. View

Shiffman S . Reflections on smoking relapse research. Drug Alcohol Rev. 2006; 25(1):15-20. DOI: 10.1080/09595230500459479. View

Fryer J, Lukas R . Antidepressants noncompetitively inhibit nicotinic acetylcholine receptor function. J Neurochem. 1999; 72(3):1117-24. DOI: 10.1046/j.1471-4159.1999.0721117.x. View

Ferguson S, Brodkin J, Lloyd G, Menzaghi F . Antidepressant-like effects of the subtype-selective nicotinic acetylcholine receptor agonist, SIB-1508Y, in the learned helplessness rat model of depression. Psychopharmacology (Berl). 2000; 152(3):295-303. DOI: 10.1007/s002130000531. View

Cryan J, Page M, Lucki I . Differential behavioral effects of the antidepressants reboxetine, fluoxetine, and moclobemide in a modified forced swim test following chronic treatment. Psychopharmacology (Berl). 2005; 182(3):335-44. DOI: 10.1007/s00213-005-0093-5. View

10.

Levin E, Rezvani A, Xiao Y, Slade S, Cauley M, Wells C . Sazetidine-A, a selective alpha4beta2 nicotinic receptor desensitizing agent and partial agonist, reduces nicotine self-administration in rats. J Pharmacol Exp Ther. 2009; 332(3):933-9. DOI: 10.1124/jpet.109.162073. View

11.

Kulkarni S, Singh K, Bishnoi M . Elevated zero maze: a paradigm to evaluate antianxiety effects of drugs. Methods Find Exp Clin Pharmacol. 2007; 29(5):343-8. DOI: 10.1358/mf.2007.29.5.1117557. View

12.

Gur T, Conti A, Holden J, Bechtholt A, Hill T, Lucki I . cAMP response element-binding protein deficiency allows for increased neurogenesis and a rapid onset of antidepressant response. J Neurosci. 2007; 27(29):7860-8. PMC: 6672880. DOI: 10.1523/JNEUROSCI.2051-07.2007. View

13.

Rollema H, Guanowsky V, Mineur Y, Shrikhande A, Coe J, Seymour P . Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect. Eur J Pharmacol. 2009; 605(1-3):114-6. PMC: 2707785. DOI: 10.1016/j.ejphar.2009.01.002. View

14.

Xiao Y, Fan H, Musachio J, Wei Z, Chellappan S, Kozikowski A . Sazetidine-A, a novel ligand that desensitizes alpha4beta2 nicotinic acetylcholine receptors without activating them. Mol Pharmacol. 2006; 70(4):1454-60. DOI: 10.1124/mol.106.027318. View

15.

Rabenstein R, Caldarone B, Picciotto M . The nicotinic antagonist mecamylamine has antidepressant-like effects in wild-type but not beta2- or alpha7-nicotinic acetylcholine receptor subunit knockout mice. Psychopharmacology (Berl). 2006; 189(3):395-401. DOI: 10.1007/s00213-006-0568-z. View

16.

Ring R, Malberg J, Potestio L, Ping J, Boikess S, Luo B . Anxiolytic-like activity of oxytocin in male mice: behavioral and autonomic evidence, therapeutic implications. Psychopharmacology (Berl). 2006; 185(2):218-25. DOI: 10.1007/s00213-005-0293-z. View

17.

Mineur Y, Eibl C, Young G, Kochevar C, Papke R, Gundisch D . Cytisine-based nicotinic partial agonists as novel antidepressant compounds. J Pharmacol Exp Ther. 2009; 329(1):377-86. PMC: 2670591. DOI: 10.1124/jpet.108.149609. View

18.

Malin D, Goyarzu P . Rodent models of nicotine withdrawal syndrome. Handb Exp Pharmacol. 2009; (192):401-34. DOI: 10.1007/978-3-540-69248-5_14. View

19.

Matta S, Balfour D, Benowitz N, Boyd R, Buccafusco J, Caggiula A . Guidelines on nicotine dose selection for in vivo research. Psychopharmacology (Berl). 2006; 190(3):269-319. DOI: 10.1007/s00213-006-0441-0. View

20.

Cohen A, Young R, Velazquez M, Groysman M, Noorbehesht K, Ben-Shahar O . Anxiolytic effects of nicotine in a rodent test of approach-avoidance conflict. Psychopharmacology (Berl). 2009; 204(3):541-9. PMC: 2920299. DOI: 10.1007/s00213-009-1486-7. View